Daily Daraxonrasib Pill Plus Chemo Makes Tumors Undetectable in 1 in 12 Patients
A daily pill combined with chemotherapy shrank or halted pancreatic tumors in nearly all patients in an early clinical trial, with tumors becoming undetectable on scans in one of every 12 participants, according to results presented Friday at a European oncology symposium in Barcelona.
The drug, daraxonrasib, targets a specific KRAS mutation that drives more than 90 percent of pancreatic ductal adenocarcinomas. In the phase 1/2 study of 61 previously untreated patients with metastatic disease, 90.2 percent saw their tumors stop growing and 60.7 percent experienced tumor shrinkage or disappearance, BBC News Brasil reported. Median progression-free survival reached 12.8 months, nearly double the historical 3.5 to 7.3 months seen with standard chemotherapy alone, according to data reported by VEJA and 24 Horas.
Key Clinical Takeaways:

- Daraxonrasib plus gemcitabine and nab-paclitaxel halted tumor growth in 90 percent of metastatic pancreatic cancer patients in a phase 1/2 trial.
- Tumors became undetectable on CT scans in 8.2 percent of patients, a response depth rarely seen in this disease.
- The combination nearly doubled median progression-free survival to 12.8 months versus historical controls of 3.5–7.3 months.
First KRAS inhibitor to reach first-line pancreatic cancer
Pancreatic cancer remains one of the deadliest common malignancies. In the United Kingdom, 11,500 cases are diagnosed annually with 10,200 deaths, according to Cancer Research UK. Brazil recorded 14,379 deaths in 2024, a rate of 6.8 per 100,000 inhabitants, BBC News Brasil reported. Portugal diagnosed 2,191 new cases and recorded 2,051 deaths in 2024, making it the sixth leading cause of cancer death there, according to Renascença citing the Portuguese Society of Gastroenterology.
For decades, the KRAS protein was considered “undruggable.” Daraxonrasib, developed by Revolution Medicines and marketed as Rasonque in the United States, binds to and inactivates the mutated KRAS(G12D) protein, blocking the signaling cascade that fuels tumor growth.
The FDA approved the drug as a monotherapy in July 2026 for previously treated patients, Terra reported. In September, the agency granted breakthrough therapy designation to the combination with chemotherapy for first-line use, accelerating its review, 24 Horas noted.
Daraxonrasib plus chemo shows 60.7 percent response rate
The study enrolled 61 patients with metastatic pancreatic adenocarcinoma harboring KRAS mutations who had received no prior systemic therapy. They took a daily daraxonrasib tablet alongside standard gemcitabine and nab-paclitaxel cycles. After a median follow-up of 18.3 months, the objective response rate was 60.7 percent and the disease control rate was 90.2 percent, VEJA reported. Complete radiographic responses — tumors no longer visible on CT — occurred in 8.2 percent of patients.
| Outcome | Daraxonrasib + Chemo (Phase 1/2) | Historical Chemotherapy Alone |
|---|---|---|
| Complete Response (undetectable) | 8.2% | <1% |
| Median Progression-Free Survival | 12.8 months | 3.5–7.3 months |
| Median Overall Survival (2nd line RAS mut.) | 13.2 months | 6.7 months |
Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center and lead investigator, said the combination “represents a potentially transformative advance in first-line treatment of metastatic pancreatic cancer, already exceeding the historical upper limit of overall survival of 8.5 to 11.1 months with conventional chemotherapy,” according to a statement carried by VEJA. He estimated 76.6 percent of patients were alive at one year.
“We are starting to see not only a higher percentage of tumor response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”
European review underway while US combination stays investigational
The European Medicines Agency accepted the marketing authorization application in an accelerated assessment procedure in July 2026, Terra reported. Approval in Europe remains pending national pricing and reimbursement decisions. In the United States, the drug is approved only as a single agent for previously treated patients; the first-line combination remains investigational pending the phase 3 RASolute 303 trial, which is currently enrolling newly diagnosed patients, 24 Horas reported.

Elena Garralda, president of the EORTC–NCI–AACR Symposium where the data were presented, said the results are encouraging because they show the combination “can potentially significantly improve overall survival of patients, as well as the time until tumors start growing again,” she told BBC News Brasil.
“The cancer can come back and, even if scans show no sign of it, you don’t necessarily know if you are cancer-free until more time has passed.”
Sam Godfrey of Cancer Research UK told BBC News Brasil, noting the charity called the advance the biggest in decades for pancreatic cancer patients.
What this means for other KRAS-driven cancers
Similar KRAS mutations appear in subsets of lung, colorectal, and ovarian cancers, suggesting daraxonrasib could have utility beyond the pancreas. Godfrey said he hopes “the early success we are starting to see in pancreatic cancer can be replicated in other cancer types,” he told BBC News Brasil.

For patients facing a new diagnosis of metastatic pancreatic cancer, the standard of care remains combination chemotherapy, though molecular profiling to identify KRAS mutation status is increasingly critical for clinical trial eligibility. Oncologists specializing in gastrointestinal malignancies can discuss whether enrollment in the ongoing phase 3 study or other targeted therapy trials is appropriate.
The RASolute 303 phase 3 trial is expected to read out initial efficacy data in 2027.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.